GlassScriptPhysician profile
Mukundkumar V Patel
NPI 1164411724
$2,605.61
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $40.38 · 2021: $598 · 2022: $809 · 2023: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $167 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,174.54 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $204.67 | 2019-2022 | |
| Janssen Biotech, INC. | $199.84 | 2019-2023 | Erleada |
| Emd Serono, INC. | $123.44 | 2022 | |
| Merck Sharp & Dohme LLC | $115.31 | 2019 | |
| Celgene Corporation | $105.08 | 2019-2022 | |
| Galvanize Therapeutics, INC | $98.33 | 2022 | |
| Lilly USA, LLC | $76.48 | 2019-2020 | |
| Stemline Therapeutics INC. | $58.75 | 2019 | |
| Amag Pharmaceuticals, INC. | $56.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $52.27 | 2019-2022 | |
| Foundation Medicine, INC. | $45.84 | 2019 | |
| Amgen INC. | $42.12 | 2019 | |
| Puma Biotechnology, INC. | $28.38 | 2019 | |
| Boston Scientific Corporation | $26.05 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $25.01 | 2022 | |
| Rigel Pharmaceuticals, INC. | $21.96 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $20.72 | 2019 | |
| Sobi, INC | $16.77 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.29 | 2022 | |
| Incyte Corporation | $16.23 | 2019 | |
| Astellas Pharma US INC | $16.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.74 | 2019 | |
| Kite Pharma, INC. | $14.16 | 2022 | |
| Daiichi Sankyo INC. | $12.59 | 2019 | |
| Verastem, INC. | $12.46 | 2019 | |
| Pfizer INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukundkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.